drugset / Trial / NCT00128271

Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection

NCT00128271

Phase 1 Completed 32 enrolled Peregrine Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and tolerability of bavituximab when administered via a vein as a single infusion and to examine how bavituximab behaves in the body and how it affects the amount of hepatitis C virus in individuals with chronic infection.

Timeline

Start
2005-08
Primary completion
2006-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Bavituximab Monoclonal antibody Intravenous